Neoadjuvant and Adjuvant Chemotherapy in High-risk Soft Tissue Sarcoma

• Status: Completed
• Trial end date: 2011-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Neo- and adjuvant chemotherapy is used in high-risk soft tissue sarcoma to improve systemic control. Patients in this trial are treated with 4 cycles of chemotherapy (EIA, etoposide, ifosfamide, adriamycin) preoperatively, followed by local surgery and radiotherapy. An additional 4 cycles of adjuvant chemotherapy is administered. Treatment response is assessed by MRI and CT scans and FDG-PET in a subgroup of patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Heidelberg University
• Collaborator: German Cancer Research Center

Criteria

Inclusion Criteria:

• Soft tissue sarcoma histology

• Tumor size >= 5 cm

• Deep/extracompartimental localization

• Grade 2/3 (FNCLCC)

• Patients with inadequate previous therapy

• Age 18-65 years

• normal bone marrow function

• normal liver function

• normal renal function

• Karnofsky index >=80%

Exclusion Criteria:

• Chordoma

• Chondrosarcoma

• Kaposi´ sarcoma

• Neuroblastoma

• Mesothelioma

• Osteosarcoma/Ewings´sarcoma